ArticleAmerican journal of translational research2025
Endostar and chemoradiotherapy for advanced cervical cancer: comparing efficacy and prognosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer.World journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of endostar combined with simultaneous chemoradiotherapy versus conventional treatment methods for locally advanced cervical cancer (LACC) and assess the prognosis of these patients.
methodsA retrospective analysis was conducted on the medical records of 182 LACC patients treated at Shaanxi Provincial Cancer Hospital between January 2017 and February 2021. Of these, 88 patients underwent conventional synchronous chemoradiotherapy (control group), while 94 patients received endostar combined with synchronous chemoradiotherapy (combined group). Treatment efficacy, adverse reactions, and tumor marker levels before and after treatment were compared. The 1-year and 3-year survival rates of the two groups were analyzed. Risk factors for 3-year mortality were identified through Cox regression analysis, and the prognostic predictive value of independent factors was assessed using ROC curve analysis.
resultsThe objective remission rate (ORR) in the combined group (74.47%) was significantly higher than that in the control group (54.55%,
conclusionEndostar combined with synchronous chemoradiotherapy for LACC significantly improves short-term treatment efficacy and long-term survival outcomes compared to chemoradiotherapy alone. This approach is safe and does not increase adverse effects, highlighting its potential as a superior treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.